Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Elite Pharmaceuticals ( (ELTP) ).
Elite Pharmaceuticals reported strong financial performance for its third quarter of fiscal 2026, covering the three months ended Dec. 31, 2025, highlighted by a sharp jump in revenue and profitability. Consolidated revenues reached $31.6 million, up approximately 120% from the prior-year period, while income from operations climbed to $9.0 million, about a 721% increase, and net income came in at $18.6 million.
The surge in results was driven largely by sales of newly launched lisdexamfetamine and naltrexone products, alongside robust growth across the Elite label product lines compared with the same quarter a year earlier. The performance underscores Elite’s growing traction in its targeted niche generics portfolio, suggesting an improving earnings profile and potentially stronger positioning within the competitive generic pharmaceuticals market.
The most recent analyst rating on (ELTP) stock is a Hold with a $0.47 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.
Spark’s Take on ELTP Stock
According to Spark, TipRanks’ AI Analyst, ELTP is a Neutral.
The score is driven primarily by strong current financial performance and a very favorable earnings update highlighting rapid growth and improving profitability/cash generation. These strengths are tempered by weak technical trends and a high P/E valuation, which increase sensitivity to any margin pressure or growth normalization.
To see Spark’s full report on ELTP stock, click here.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and distributing niche generic products, particularly oral, controlled-release drug formulations. The company owns multiple generic products sold nationwide under the Elite Laboratories, Inc. label, licenses additional products to TAGI Pharma, and operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, N.J.
Elite’s business model centers on supplying differentiated generic medications in the U.S. market, leveraging its specialized production capabilities and regulatory-compliant infrastructure. This positioning allows Elite to target narrower therapeutic segments where complex formulations and controlled-release technologies can provide competitive advantages over more commoditized generic offerings.
Average Trading Volume: 677,665
Technical Sentiment Signal: Sell
Current Market Cap: $472.8M
See more insights into ELTP stock on TipRanks’ Stock Analysis page.